BioNTech (BNTX) vs Insmed (INSM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioNTech (BNTX) has outperformed Insmed (INSM) over the past year, losing 7.2% versus a loss of 37.9%. Over five years, INSM leads with a +279.3% price change compared with -60.9% for BNTX. BioNTech is the larger company by market cap ($24.36 billion vs $21.97 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | INSM |
|---|---|---|
| Share price | $96.96 | $100.60 |
| Market cap | $24.36B | $21.97B |
| 1-day change | +5.32% | +0.12% |
| YTD return | +1.85% | -42.27% |
| 1-year return | -7.20% | -37.90% |
| 5-year return | -60.85% | +279.31% |
| Forward P/E | — | 127.76 |
| EPS (TTM) | $-7.83 | $-4.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $606.42M |
| Revenue growth (YoY) | — | +66.73% |
| Net income (latest FY) | — | $-1.28B |
| Gross margin | — | 79.73% |
| Operating margin | — | -205.59% |
| Net margin | — | -210.54% |
| 52-week high | $124.00 | $212.75 |
| 52-week low | $79.52 | $90.39 |
| Distance from 52-week high | -21.81% | -52.71% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +19.42% | +96.56% |
| Average volume | 1.16M | 2.60M |
| Shares outstanding | 251.20M | 218.38M |
| Employees | 7,807 | 1,664 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BNTX has outperformed INSM by 30.7 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Insmed
INSM stock →Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,664 employees
BNTX vs INSM FAQ
Which is bigger, BioNTech or Insmed?
BioNTech (BNTX) is larger, with a market capitalization of $24.36B compared with $21.97B for Insmed (INSM).
Which stock has performed better over the past year, BNTX or INSM?
BNTX returned -7.20% over the past 12 months, compared with -37.90% for INSM (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Insmed in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioNTech and Biotechnology: Pharmaceutical Preparations for Insmed.